Hematologic Malignancies and Cellular Therapy

Harry Paul Erba, MD, PhD

Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address harry.erba@duke.edu

I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine.  I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies.  I am also the Chair of the SWOG Leukemia Committee.  I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia.  Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.  

Education and Training

  • Research Fellowship in Medicine, Medicine, Harvard Medical School, 1991 - 1993
  • Research/Clinical Fellowship in Medicine, Medicine, Brigham and Women's Hospital, 1991 - 1992
  • Clinical Fellow in Medicine, Medicine, Harvard Medical School, 1988 - 1991
  • Residency Physician, Medicine, Brigham and Women's Hospital, 1988 - 1990
  • Ph.D., Stanford University, 1988
  • M.D., Stanford University, School of Medicine, 1988

Grants

Publications

Advani, Anjali S., Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Min Fang, Matthew J. Wieduwilt, Ibrahim Aldoss, et al. “SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.” J Clin Oncol 40, no. 14 (May 10, 2022): 1574–82. https://doi.org/10.1200/JCO.21.01766.

PMID
35157496
Full Text

Shanafelt, Tait D., Xin Victoria Wang, Curtis A. Hanson, Elisabeth M. Paietta, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, et al. “Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial.” Blood, April 15, 2022. https://doi.org/10.1182/blood.2021014960.

PMID
35427411
Full Text

Wang, Xin Victoria, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O’Brien, et al. “Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.” Blood 138, no. 26 (December 30, 2021): 2810–27. https://doi.org/10.1182/blood.2020010146.

PMID
34407545
Full Text

Nazha, Aziz, Rami Komrokji, Manja Meggendorfer, Xuefei Jia, Nathan Radakovich, Jacob Shreve, C Beau Hilton, et al. “Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.” J Clin Oncol 39, no. 33 (November 20, 2021): 3737–46. https://doi.org/10.1200/JCO.20.02810.

PMID
34406850
Full Text

DiNardo, Courtney D., Eytan M. Stein, Arnaud Pigneux, Jessica K. Altman, Robert Collins, Harry P. Erba, Justin M. Watts, et al. “Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.” Leukemia 35, no. 11 (November 2021): 3278–81. https://doi.org/10.1038/s41375-021-01229-x.

PMID
33772143
Full Text

Ruppert, Amy S., Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Steven Coutre, Jennifer R. Brown, et al. “Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.” Leukemia 35, no. 10 (October 2021): 2854–61. https://doi.org/10.1038/s41375-021-01342-x.

PMID
34274940
Full Text

Othus, Megan, Guillermo Garcia-Manero, John Godwin, James Weick, Derek Stirewalt, Frederick Appelbaum, Harry Erba, and Elihu Estey. “Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.” Leuk Lymphoma 62, no. 8 (August 2021): 1967–72. https://doi.org/10.1080/10428194.2021.1885663.

PMID
33719833
Full Text

Moseley, Anna, Megan Othus, Guillermo Garcia-Manero, Frederick R. Appelbaum, Harry P. Erba, and Roland B. Walter. “Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.” Leuk Lymphoma 62, no. 7 (July 2021): 1774–77. https://doi.org/10.1080/10428194.2021.1881512.

PMID
33560164
Full Text

Patel, Jay L., Mehrdad Abedi, Christopher R. Cogle, Harry P. Erba, Kathryn Foucar, Guillermo Garcia-Manero, David L. Grinblatt, et al. “Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.” Int J Lab Hematol 43, no. 3 (June 2021): 426–32. https://doi.org/10.1111/ijlh.13400.

PMID
33220019
Full Text

Pabon, Cindy M., Zhiguo Li, Therese Hennig, Carlos de Castro, Jadee L. Neff, Mitchell E. Horwitz, Thomas W. LeBlanc, et al. “Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant.” Blood Cancer J 11, no. 5 (May 16, 2021): 92. https://doi.org/10.1038/s41408-021-00481-9.

PMID
33994546
Full Text

Pages